Sequence:

H-His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys(AEEAc-AEEAc-γ-Glu-17-carboxyheptadecanoyl)-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-OH

CAS NO.: 910463-68-2

Molecular Formula: C187H291N45O59

Molecular Weight: 4,113.64

Appearance:White Crystalline Powder

Purity: 99.38%

Identification: Infrared Absorption

Loss On Drying: ≤0.2%

Residue On Ignition: ≤0.3%

Chloride:≤0.05%

Sulfate:≤0.03%

Heavy Metals:≤0.0015%

Application:

1. Used as both injection-type or oral-type drug.

2. Used for the treatment of obesity.

3. Improve cardiovascular function

4. Treatment of type 2 diabetes in adults

About Semaglutide:

Semaglutide(Ozempic) is a glucagon-like peptide-1 analogue for once-weekly subcutaneous treatment of type 2 diabetes.Semaglutide is a pharmaceutical drug which is used for the treatment of type 2 diabetes. Semaglutide has demonstrated the potential to improve the treatment of type 2 diabetes and the positive recommendation from the Advisory Committee marks an important step towards making semaglutide available to adults with type 2 diabetes in the US. Semaglutide(Ozempic), a newly once-weekly glucagon like peptide-1 (GLP-1) receptor agonist, has showed a favorable effect on glycaemic control and weight reduction in type 2 diabetes mellitus (T2DM).

In humans semaglutide is chemically similar to glucagon-like peptide-1 (GLP-1).

Semaglutide is a glucagon-like peptide-1 (GLP-1) analog and functions as a GLP-1 agonist.

Furthermore, semaglutide demonstrated a significant, beneficial effect on cardiovascular outcomes and a safety profile similar to that of other GLP-1 receptor agonists.Semaglutide also improves cardiovascular function, reduces the risk of stroke by 39%, and reduces the risk of myocardial infarction by 26%.